Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628887 | 0.80 | MAPT (0.38) | ALDH1A1POLBMAPTLMNAKDM4E | |
| SCHEMBL5290084 | 0.80 | ALDH1A1 (0.38) | ALDH1A1POLBMAPTGRIA1GRIA2 | |
| SCHEMBL2930014 | 0.79 | BRD4 (0.32) | ALDH1A1POLBMAPT | |
| SCHEMBL2603746 | 0.75 | POLB (0.40) | ALDH1A1POLBMAPTKDM4E | |
| SCHEMBL725456 | 0.74 | ALDH1A1 (0.41) | ALDH1A1POLBMAPT | |
| SCHEMBL27989702 | 0.72 | BRD4 (0.32) | ALDH1A1POLBMAPT | |
| SCHEMBL7632015 | 0.70 | GRM8 (0.36) | ALDH1A1POLBMAPTCYP2C9GRIA1 | |
| SCHEMBL16247195 | 0.66 | APAF1 (0.46) | ALDH1A1POLBMAPTGRIA1LMNA | |
| SCHEMBL2976953 | 0.65 | ALDH1A1 (0.33) | ALDH1A1POLBMAPTKDM4EKMT2A | |
| Water SCHEMBL7316641 | 0.65 | L3MBTL1 (0.36) | ALDH1A1MAPTLMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321203-A1 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11723959-B2 | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide | HALOZYME, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| EP-3956026-A1 | P16INK4A INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | SORBONNE UNIVERSITE (FR) | 2022-02-23 | — | — | EP | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210023184-A1 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | DELIATROPH PHARMACEUTICALS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10898551-B2 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof | HALOZYME, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020212597-A1 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | SORBONNE UNIVERSITE (FR) | 2020-10-22 | — | — | WO | disclosed |
| US-10588983-B2 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190224286-A1 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10286044-B2 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof | HALOZYME, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-1603541-A4 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME INC (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1636248-A4 | HUMAN CHONDROITINASE GLYCOPROTEIN (CHASEGP), PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME INC (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006091871-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | HALOZYME THERAPEUTICS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060104968-A1 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases | HALOZYME, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1636248-A2 | HUMAN CHONDROITINASE GLYCOPROTEIN (CHASEGP), PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | Halozyme, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1603541-A2 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | Halozyme, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050260186-A1 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20040268425-A1 | use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms | DELIATROPH PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004078140-A2 | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004058147-A2 | HUMAN CHONDROITINASE GLYCOPROTEIN (CHASEGP), PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | HALOZYME, INC. (US) | 2004-07-15 | — | — | WO | disclosed |